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Are we ready to demystify age in glioblastoma? 
 
The strong negative impact on outcome of higher age in glioma patients has been noted ever 
since larger populations of glioma patients have been analyzed. However, the cut-off for 
defining “elderly” has remained controversial, and there is now little doubt that higher age is a 
surrogate marker for a changing biology of gliomas with age. In fact, it has often been 
(inofficially) speculated (at conferences) that advanced neuro-oncologists simply define 
“elderly” as their own age plus 15. Undoubtedly, we must and can do better. 
 
In this issue of Neuro-Oncology, Scott and colleagues (1) report a retrospective analysis of 
outcome by treatment administered in 206 patients with glioblastoma aged 70 or more 
diagnosed between May 1979 and September 2007. These patients had a median age of 75 
years and a median overall survival of 4.5 months. Multivariate analysis confirmed higher 
Karnofsky score, surgery beyond biopsy, radiotherapy, and chemotherapy to be associated 
with longer survival. Although this analysis thus spans almost three decades of development 
in Neuro-Oncology, there is apparently a consistent trend for less aggressive treatment in the 
elderly, and (over)treated patients lived longer than (under)treated patients. 
 
Altogether, Neuro-Oncology should be moving to concepts that characterize and understand 
age as a surrogate marker of a specific biological character of disease rather than the 
proximate course of poor outcome per se. The first step was the delineation and segregation 
of glio(blasto)mas carrying isocitrate dehydrogenase (IDH) mutations. Across all glioma 
entities, IDH-mutant tumors show a more favourable outcome. There are almost no patients 
with IDH-mutant anaplastic astrocytomas and glioblastomas above the age of 60. 
Accordingly, the differential distribution of IDH mutations may account for some of the 
apparent unfavourable prognostic impact of age hitherto attributed to age per se (2). A next 
step may be resolving the apparent discrepancy between the high rate of O6-
methylguanylmethyltransferase (MGMT) promoter hypermethylation (3) and the still 
generally poor(er) outcome in the elderly. 
 
Undoubtedly, the analysis of Scott and colleagues (1) justifies to explore the role of more 
aggressive approaches of treatment in elder glioblastoma patients. However, as long as we 
continue to compare the effects of aggressive treatment in good prognosis patients with the 
effects of less aggressive treatment in poor prognosis patients, we will not be able to justify a 
change in the standards of care. In this regard, it is important to note that the benefit derived 
from concomitant and adjuvant temozolomide decreases with increasing age (4). Whether this 
reflects lower activity or poorer tolerance of combined modality treatment, has remained 
controversial. 
 
Fortunately, Neuro-Oncology is now rapidly moving to a definition of standards of care for 
older patients with glioblastoma based on data from randomized trials. The superiority of 
radiotherapy over best supportive is no longer disputed (5). Radiotherapy alone has been 
challenged by temozolomide chemotherapy alone both in the Nordic trial (6) and the NOA-08 
trial (7). While temozolomide was equieffective to radiotherapy in the Nordic trial, but not in 
NOA-08, it is still conceivable that these apparent differences dissolve upon the analysis of 
survival by molecular markers and first-line and salvage treatment administered in these 
studies. Meanwhile, the NCIC EORTC trial, which compares hypofractionated radiotherapy 
alone versus hypofractionated radiotherapy plus concomitant and adjuvant temozolomide 
chemotherapy, takes the next step and is well under way 
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